{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:40:10Z","timestamp":1758901210658,"version":"3.44.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12325-025-03323-3","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T07:57:19Z","timestamp":1755590239000},"page":"5187-5201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Triple Fixed Dose Combination of Dapagliflozin\u2009+\u2009Sitagliptin\u2009+\u2009Metformin IR in Indian Patients with Type 2 Diabetes Mellitus: A Randomized, Phase 3 Study in Comparison with Dual FDC Sitagliptin\u2009+\u2009Metformin IR"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct01468246","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Mahendra Pal","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ambrish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakash","family":"Kurmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh Kumar","family":"Gangwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Naganna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravikumar","family":"Sethuraman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vrindavani","family":"Dhumal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sapan","family":"Behera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyush M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8690-3302","authenticated-orcid":false,"given":"Dipak M.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalit K.","family":"Lakhwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pravin S.","family":"Ghadge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyog C.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadhna J.","family":"Joglekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"3323_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan B, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109\u201319.","journal-title":"Diabetes Res Clin Pract"},{"key":"3323_CR2","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S2213-8587(23)00119-5","volume":"11","author":"R Anjana","year":"2023","unstructured":"Anjana R, Unnikrishnan R, Deepa M, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR INDIAB-17). Lancet Diabetes Endocrinol. 2023;11:474\u201389.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3323_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2337\/db09-9028","volume":"58","author":"RA Defronzo","year":"2009","unstructured":"Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773\u201395.","journal-title":"Diabetes"},{"key":"3323_CR4","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.2337\/diab.41.12.1575","volume":"41","author":"G Gulli","year":"1992","unstructured":"Gulli G, Ferrannini E, Stern M, Haffner S, DeFronzo RA. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes. 1992;41:1575\u201386.","journal-title":"Diabetes"},{"key":"3323_CR5","doi-asserted-by":"publisher","first-page":"909","DOI":"10.7326\/0003-4819-113-12-909","volume":"113","author":"JH Warram","year":"1990","unstructured":"Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990;113:909\u201315.","journal-title":"Ann Intern Med"},{"key":"3323_CR6","doi-asserted-by":"crossref","unstructured":"DeFronzo\u2008RA. Lilly lecture 1987. The triumvirate: \u03b2-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes\u20081988;37:667\u2013687.","DOI":"10.2337\/diab.37.6.667"},{"key":"3323_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00125-003-1263-9","volume":"47","author":"A Gastaldelli","year":"2004","unstructured":"Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA, San Antonio metabolism study. Beta-cell dysfunction and glucose intolerance: results from the San Antonio Metabolism (SAM) study. Diabetologia. 2004;47:31\u20139.","journal-title":"Diabetologia"},{"key":"3323_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1210\/jc.2004-1133","volume":"90","author":"E Ferrannini","year":"2005","unstructured":"Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. \u03b2-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab. 2005;90:493\u2013500.","journal-title":"J Clin Endocrinol Metab"},{"key":"3323_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/bmj.310.6972.83","volume":"310","author":"United Kingdom Prospective Diabetes Study","year":"1995","unstructured":"United Kingdom Prospective Diabetes Study. 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310:83\u20138.","journal-title":"BMJ"},{"key":"3323_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S2213-8587(20)30022-X","volume":"8","author":"GC Weir","year":"2020","unstructured":"Weir GC, Gaglia J, Bonner-Weir S. Inadequate \u03b2-cell mass is essential for the pathogenesis of type 2 diabetes. Lancet Diabetes Endocrinol. 2020;8:249\u201356.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3323_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"I Stratton","year":"2000","unstructured":"Stratton I, Adler A, Neil H. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405\u201312.","journal-title":"BMJ"},{"key":"3323_CR12","doi-asserted-by":"crossref","unstructured":"Buse J, Wexler D, Tsapas A. Update to: management of hyperglycemia in type 2 diabetes. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [published correction appears in Diabetes Care 2020;43:1670]. Diabetes Care. 2018; 43: p. 487\u2013493.","DOI":"10.2337\/dci19-0066"},{"key":"3323_CR13","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.2337\/dc19-2424","volume":"43","author":"P Le","year":"2020","unstructured":"Le P, Chaitoff A, Misra-Hebert A, Ye W, Herman W, Rothberg M. Use of antihyperglycemic medications in U.S. adults: an analysis of the National Health and Nutrition Examination Survey. Diabetes Care. 2020;43:1227\u201333.","journal-title":"Diabetes Care"},{"key":"3323_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2337\/dc17-1414","volume":"41","author":"O Montvida","year":"2018","unstructured":"Montvida O, Shaw J, Atherton J, Stringer F, Paul S. Long-term trends in antidiabetes drug usage in the U.S.: real-world evidence in patients newly diagnosed with type 2 diabetes. Diabetes Care. 2018;41:69\u201378.","journal-title":"Diabetes Care"},{"key":"3323_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1046\/j.1464-5491.2002.00689.x","volume":"19","author":"P Donnan","year":"2002","unstructured":"Donnan P, Macdonald T, Morris A. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19:279\u201384.","journal-title":"Diabet Med"},{"key":"3323_CR16","doi-asserted-by":"publisher","first-page":"32412","DOI":"10.1371\/journal.pone.0032412","volume":"7","author":"M Tiv","year":"2012","unstructured":"Tiv M, Viel J, Mauny F, Eschw\u00e8ge E, Weill A, Fournier C. Medication adherence in type 2 diabetes: the ENTRED study 2007, a French population-based study. PLoS ONE. 2012;7:32412.","journal-title":"PLoS ONE"},{"key":"3323_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.4103\/2230-8210.152739","volume":"19","author":"M John","year":"2015","unstructured":"John M, Gopinath D, Kalra S. Triple fixed drug combinations in type 2 diabetes. Indian J Endocrinol Metab. 2015;19:311\u20133.","journal-title":"Indian J Endocrinol Metab"},{"key":"3323_CR18","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"S Inzucchi","year":"2012","unstructured":"Inzucchi S, Bergenstal R, Buse J. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364\u201379.","journal-title":"Diabetes Care"},{"key":"3323_CR19","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee; 9. Pharmacologic Approaches to Glycemic Treatment:\u00a0Standards of Care in Diabetes\u20142024.\u00a0Diabetes Care\u00a01 January 2024; 47 (Supplement_1): S158\u2013S178.","DOI":"10.2337\/dc24-S009"},{"key":"3323_CR20","doi-asserted-by":"publisher","first-page":"536","DOI":"10.4158\/EP13176.CS","volume":"19","author":"A Garber","year":"2013","unstructured":"Garber A, Abrahamson M, Barzilay J, et al. American Association of Clinical Endocrinologists\u2019 comprehensive diabetes management algorithm 2013 consensus statement-executive summary. Endocr Pract. 2013;19:536\u201357.","journal-title":"Endocr Pract"},{"key":"3323_CR21","doi-asserted-by":"publisher","first-page":"740","DOI":"10.2337\/dc13-0467","volume":"37","author":"S Jabbour","year":"2014","unstructured":"Jabbour S, Hardy E, Sugg J, Parikh S. Study 10 Group. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37:740\u201350.","journal-title":"Diabetes Care"},{"key":"3323_CR22","doi-asserted-by":"publisher","first-page":"376","DOI":"10.2337\/dc14-1142","volume":"38","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38:376\u201383.","journal-title":"Diabetes Care"},{"key":"3323_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4093\/dmj.2023.0128","volume":"48","author":"Y Park","year":"2024","unstructured":"Park Y, Sohn M, Lee S, Lim S. Two-year therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and empagliflozin in drug-na\u00efve type 2 diabetes mellitus patients. Diabetes Metab J. 2024;48:253\u201364.","journal-title":"Diabetes Metab J"},{"key":"3323_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12325-011-0096-z","volume":"29","author":"M Benford","year":"2012","unstructured":"Benford M, Milligan G, Pike J, Anderson P, Piercy J, Fermer S. Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. Adv Ther. 2012;29:26\u201340.","journal-title":"Adv Ther"},{"key":"3323_CR25","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.2337\/dc16-2372","volume":"40","author":"SE Inzucchi","year":"2017","unstructured":"Inzucchi SE. Is it time to change the type 2 diabetes treatment paradigm? No! metformin should remain the foundation therapy for type 2 diabetes. Diabetes Care. 2017;40:1128\u201332.","journal-title":"Diabetes Care"},{"key":"3323_CR26","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1007\/s12325-023-02523-z","volume":"40","author":"R Sahay","year":"2023","unstructured":"Sahay R, Giri R, Shembalkar J, et al. Fixed-dose combination of dapagliflozin + sitagliptin + metformin in patients with type 2 diabetes poorly controlled with metformin: phase 3, randomized comparison with dual combinations. Adv Ther. 2023;40:3227\u201346.","journal-title":"Adv Ther"},{"key":"3323_CR27","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s12325-024-03037-y","volume":"42","author":"AK Singh","year":"2024","unstructured":"Singh AK, Das AK, Murthy LS, et al. Efficacy of Dapagliflozin + Sitagliptin + Metformin Versus Sitagliptin + Metformin in T2DM Inadequately Controlled on Metformin Monotherapy: A Multicentric Randomized Trial. Adv Ther. 2024;42:801\u201312.","journal-title":"Adv Ther"},{"key":"3323_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s13410-024-01321-9","volume":"44","author":"AK Singh","year":"2024","unstructured":"Singh AK, Sahay R, Gil N, et al. A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial. Int J Diabetes Dev Countries. 2024;44:67\u201376.","journal-title":"Int J Diabetes Dev Countries"},{"issue":"12","key":"3323_CR29","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.2337\/dc17-1624","volume":"40","author":"G Agiostratidou","year":"2017","unstructured":"Agiostratidou G, Anhalt H, Ball D, et al. Standardizing clinically meaningful outcome measures beyond HbA1c for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care. 2017;40(12):1622\u201330.","journal-title":"Diabetes Care"},{"key":"3323_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2337\/dci19-0066","volume":"43","author":"JB Buse","year":"2019","unstructured":"Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2019;43:487\u201393.","journal-title":"Diabetes Care"},{"issue":"2","key":"3323_CR31","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"A Merovci","year":"2014","unstructured":"Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124(2):509\u201314. https:\/\/doi.org\/10.1172\/JCI70704.","journal-title":"J Clin Invest"},{"key":"3323_CR32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"S Wiviott","year":"2019","unstructured":"Wiviott S, Raz I, Bonaca M, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"3323_CR33","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s13300-019-0562-1","volume":"10","author":"A Singh","year":"2019","unstructured":"Singh A, Unnikrishnan A, Zargar A, et al. Evidence-based consensus on positioning of SGLT2i in type 2 diabetes mellitus in Indians. Diabetes Ther. 2019;10:393\u2013428.","journal-title":"Diabetes Ther"},{"key":"3323_CR34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4103\/2230-8210.176353","volume":"20","author":"A Singh","year":"2016","unstructured":"Singh A, Singh R. Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: a systematic review of current evidence. Indian J Endocrinol Metab. 2016;20:245\u201353.","journal-title":"Indian J Endocrinol Metab"},{"key":"3323_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.\u00a0BMJ 2000;321:405-12","journal-title":"BMJ"},{"issue":"3","key":"3323_CR36","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232\u201342.","journal-title":"N Engl J Med"},{"key":"3323_CR37","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"D Drucker","year":"2006","unstructured":"Drucker D, Nauck M. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696\u2013705.","journal-title":"Lancet"},{"key":"3323_CR38","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.4158\/EP14489.OR","volume":"20","author":"L Hansen","year":"2014","unstructured":"Hansen L, Iqbal N, Ekholm E, Cook W, Hirshberg B. Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy. Endocr Pract. 2014;20:1187\u201397.","journal-title":"Endocr Pract"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03323-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03323-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03323-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:09:14Z","timestamp":1758899354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03323-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3323"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03323-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mahendra Pal Singh, Sandeep Gupta, Manish Singh, Ambrish C, Prakash Kurmi, Dinesh Kumar Gangwani, J Naganna, and Ravikumar Sethuraman were the study investigators and they received grants from sponsors for conducting the study at their respective sites. Dipak M Patil, Pravin S Ghadge, and Suyog C Mehta are full-time employees of Sun Pharma Laboratories Ltd. Vrindavani Dhumal, Sapan Behera, Piyush M Patel, and Lalit K Lakhwani were full-time employees of Sun Pharma Laboratories Ltd. when conducting the study. Sadhna J Joglekar was an employee at Sun Pharma when conducting this study. She is currently employed by Novartis. The views expressed in the article are authors' views and do not necessarily reflect the views or official position of Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was approved by institutional ethics committees at all participating sites. The sponsor ensured that all the necessary ethics reviews and approvals were obtained and that the clinical study was conducted in accordance with Good Clinical Practice (GCP) guidelines as defined by the International Council for Harmonisation (ICH), the Declaration of Helsinki, the New Drugs and Clinical Trials Rules, 2019, and the 2017 guidelines issued by the Indian Council of Medical Research. Informed consent was obtained in writing from all participants before any screening procedures took place.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}